Hrt Financial LP Nkarta, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.19 - $5.17 $43,188 - $101,957	19,721 New	19,721 $43,000
Q4 2022 Feb 10, 2023	BUY	$5.14 - $14.35 $709,057 - $1.98 Million	137,949 New	137,949 $826,000
Q2 2022 Aug 12, 2022	SELL	$7.77 - $19.44 $254,257 - $636,135	-32,723 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$8.66 - $14.99 $403,521 - $698,474	-46,596 Reduced 58.75%	32,723 $372,000
Q4 2021 Feb 14, 2022	BUY	$12.79 - $26.88 $816,142 - $1.72 Million	63,811 Added 411.47%	79,319 $1.22 Million
Q3 2021 Nov 15, 2021	SELL	$26.67 - $38.76 $433,494 - $630,005	-16,254 Reduced 51.17%	15,508 $431,000
Q2 2021 Aug 16, 2021	BUY	$23.94 - $36.68 $760,382 - $1.17 Million	31,762 New	31,762 $1.01 Million

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $127M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.